Eukaryotic RNA 5'-End NAD+ Capping and DeNADding.
Trends in cell biology
confidence
Key findings
Review of NAD+ capping and deNADding on mRNA; no clinical or biological endpoints reported.
View source on PubMed (PMID 29544676) ↗
- Sample size
- N/A
- Population
- Not applicable (review article on eukaryotic mRNA capping)
- Dosing
- N/A
- Duration
- N/A
- Route
- N/A
- Blinding
- not_reported
- Controls
- not_reported
- Drug class
- coenzyme
Full abstract
A hallmark of eukaryotic mRNAs has long been the 5'-end m7G cap. This paradigm was recently amended by recent reports that Saccharomyces cerevisiae and mammalian cells also contain mRNAs carrying a novel nicotinamide adenine dinucleotide (NAD+) cap at their 5'-end. The presence of an NAD+ cap on mRNA uncovers a previously unknown mechanism for controlling gene expression through nucleotide metabolite-directed mRNA turnover. In contrast to the m7G cap that stabilizes mRNA, the NAD+ cap targets RNA for rapid decay in mammalian cells through the DXO non-canonical decapping enzyme which removes intact NAD+ from RNA in a process termed 'deNADding'. This review highlights the identification of NAD+ caps, their mode of addition, and their functional significance in cells.